We are live on ! Find out more
TPST icon

Tempest Therapeutics

36 hedge funds and large institutions have $73.9M invested in Tempest Therapeutics in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more capital inflows, than outflows

Capital inflows: $5.13M | Capital outflows: $2.34M

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 35 → 36 (+1)

0.88% more ownership

Funds ownership: 42.69% → 43.56% (+0.88%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
5
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TPST Hedge Fund Activity: Q4 2013 in Review

36 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2013, worth a combined $73.9M — down 2.3% from $75.7M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TPST positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Third Security, opening a new position worth an estimated $2.55M. The largest seller was JP Morgan Chase, cutting an estimated $1.15M.

  • 36 institutional investors held Tempest Therapeutics (TPST) as of Q4 2013, up from 35 in Q3 2013.
  • Funds reported $73.9M of Tempest Therapeutics stock for Q4 2013, down 2.3% quarter-over-quarter.
  • 5 funds opened new Tempest Therapeutics positions in Q4 2013 and 4 closed out, a net change of +1 holder.
  • The largest Tempest Therapeutics buyer in Q4 2013 was Third Security, an estimated $2.55M added.
  • The largest Tempest Therapeutics seller in Q4 2013 was JP Morgan Chase, an estimated $1.15M sold.

Based on aggregated 13F filings for Q4 2013.